SG Americas Securities LLC Sells 10,188 Shares of TransMedics Group, Inc. $TMDX

SG Americas Securities LLC reduced its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 72.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,938 shares of the company’s stock after selling 10,188 shares during the period. SG Americas Securities LLC’s holdings in TransMedics Group were worth $528,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Opal Wealth Advisors LLC bought a new position in TransMedics Group during the 2nd quarter valued at approximately $26,000. Smartleaf Asset Management LLC increased its stake in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after buying an additional 135 shares during the period. Quarry LP increased its stake in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. Sound Income Strategies LLC bought a new position in shares of TransMedics Group during the second quarter valued at approximately $48,000. Finally, CWM LLC lifted its stake in TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after acquiring an additional 155 shares during the period. 99.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TMDX. Morgan Stanley boosted their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Jefferies Financial Group initiated coverage on shares of TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective for the company. Finally, Zacks Research downgraded TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Trading Down 0.2%

NASDAQ:TMDX opened at $145.75 on Thursday. The firm has a market capitalization of $4.98 billion, a P/E ratio of 59.01 and a beta of 2.05. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $148.50. The company’s 50-day simple moving average is $121.71 and its 200 day simple moving average is $121.82.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. During the same period last year, the business earned $0.12 earnings per share. The business’s revenue was up 32.2% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. This trade represents a 17.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the transaction, the director directly owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. This represents a 59.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.